Travere Therapeutics 주식 (NASDAQ: TVTX)

에 대한 최신 뉴스 Travere Therapeutics (NASDAQ:TVTX) 주식

Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

COST

MITQ

NVNO

SCHL

TVTX

금요일 오전 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 코스트코 홀세일(NASDAQ:COST)는 4분기 긍정적인 실적을 발표했지만, 매출은 예상에 미치지 못했다. 이 회사는 분기 매출이 796.97억 달러로, 컨센서스 추정치인 799.73억 달러를 밑돌았다고 보고했다. 이 회원제 소매업체는 분기당 주당 순이익이 5.29달러로, 애널리스트 추정치인 5.08달러를 초과했다고 보고했다. 코스트코의 주식은 시간외 거래에서 1.4% 하락한 888.62달러에 거래되었다.

금요일 주목해야 할 주식: 코스트코, 스콜라스틱, 무빙 이미지 그리고 2종목

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics Inc

<p>Financial giants have made a conspicuous bullish move on PDD Holdings. Our analysis of options history for PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) revealed 87 unusual trades.</p>
<p>Delving into the details, we found 44% of traders were bullish, while 39% showed bearish tendencies. Out of all the trades we spotted, 27 were puts, with a value of $1,964,219, and 60 were calls, valued at $8,300,647.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $230.0 for PDD Holdings over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for PDD Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across PDD Holdings's significant trades, within a strike price range of $100.0 to $230.0, over the past month.</p>
<h3>PDD Holdings Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960931_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.45</td>
<td>$7.9</td>
<td>$8.31</td>
<td>$115.00</td>
<td>$2.0M</td>
<td>4.7K</td>
<td>5.0K</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.15</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$115.00</td>
<td>$2.0M</td>
<td>4.7K</td>
<td>2.5K</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$28.05</td>
<td>$27.75</td>
<td>$27.8</td>
<td>$144.00</td>
<td>$247.4K</td>
<td>0</td>
<td>139</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$38.7</td>
<td>$38.45</td>
<td>$38.45</td>
<td>$155.00</td>
<td>$192.2K</td>
<td>1.0K</td>
<td>50</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.3</td>
<td>$120.00</td>
<td>$184.5K</td>
<td>4.2K</td>
<td>654</td>
</tr>
</tbody>
</table>
</p>
<h3>About PDD Holdings</h3>
<p>PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. PDD aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from the increased productivity and new opportunities. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.</p>
<p>Following our analysis of the options activities associated with PDD Holdings, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of PDD Holdings</h3>
<ul>
<li>Trading volume stands at 6,199,920, with PDD's price up by 3.47%, positioned at $117.96.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 3 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for PDD Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Spotlight on PDD Holdings: Analyzing the Surge in Options Activity

<p>Benzinga's options scanner just detected over 30 options trades for <strong>Freeport-McMoRan</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) summing a total amount of $2,124,128.</p>
<p>At the same time, our algo caught 7 for a total amount of 381,224.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $33.0 and $55.0 for Freeport-McMoRan, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Freeport-McMoRan stands at 3474.58, with a total volume reaching 28,080.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Freeport-McMoRan, situated within the strike price corridor from $33.0 to $55.0, throughout the last 30 days.</p>
<h3>Freeport-McMoRan 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960926_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.95</td>
<td>$3.9</td>
<td>$3.94</td>
<td>$45.00</td>
<td>$338.1K</td>
<td>351</td>
<td>876</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.62</td>
<td>$1.61</td>
<td>$1.62</td>
<td>$46.00</td>
<td>$157.9K</td>
<td>4.0K</td>
<td>2.2K</td>
</tr>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.36</td>
<td>$1.31</td>
<td>$1.32</td>
<td>$42.00</td>
<td>$132.0K</td>
<td>8.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.8</td>
<td>$1.78</td>
<td>$1.79</td>
<td>$44.00</td>
<td>$118.2K</td>
<td>3.6K</td>
<td>745</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.15</td>
<td>$45.00</td>
<td>$108.0K</td>
<td>3.7K</td>
<td>577</td>
</tr>
</tbody>
</table>
</p>
<h3>About Freeport-McMoRan</h3>
<p>Freeport-McMoRan Inc is an international mining company. It has organized its mining operations into four primary divisions: North America copper mines, South America mining, Indonesia mining and Molybdenum mines. Its reportable segments include the Morenci, Cerro Verde and Grasberg (Indonesia mining) copper mines, the Rod &amp; Refining operations and Atlantic Copper Smelting and Refining. It derives key revenue from the sale of Copper.</p>
<p>Following our analysis of the options activities associated with Freeport-McMoRan, we pivot to a closer look at the company's own performance.</p>
<h3>Freeport-McMoRan's Current Market Status</h3>
<ul>
<li>With a trading volume of 7,082,008, the price of FCX is up by 1.81%, reaching $43.48.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 65 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Freeport-McMoRan</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $54.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Freeport-McMoRan, targeting a price of $52.<br />
&#x2A; An analyst from Raymond James persists with their Outperform rating on Freeport-McMoRan, maintaining a target price of $57. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Freeport-McMoRan, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Spotlight on Freeport-McMoRan: Analyzing the Surge in Options Activity

<p>Deep-pocketed investors have adopted a bearish approach towards Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SNOW usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 86 extraordinary options activities for Snowflake. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 39% leaning bullish and 52% bearish. Among these notable options, 62 are puts, totaling $2,880,105, and 24 are calls, amounting to $1,076,331.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $80.0 and $200.0 for Snowflake, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Snowflake stands at 930.06, with a total volume reaching 10,549.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Snowflake, situated within the strike price corridor from $80.0 to $200.0, throughout the last 30 days.</p>
<h3>Snowflake Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960921_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$43.95</td>
<td>$43.8</td>
<td>$43.95</td>
<td>$170.00</td>
<td>$127.4K</td>
<td>5</td>
<td align="right">29</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$14.05</td>
<td>$14.0</td>
<td>$14.0</td>
<td>$130.00</td>
<td>$106.4K</td>
<td>509</td>
<td align="right">164</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.56</td>
<td>$2.5</td>
<td>$2.56</td>
<td>$160.00</td>
<td>$102.4K</td>
<td>3.2K</td>
<td align="right">533</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$19.3</td>
<td>$19.25</td>
<td>$19.25</td>
<td>$140.00</td>
<td>$88.6K</td>
<td>1.8K</td>
<td align="right">98</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$4.9</td>
<td>$4.85</td>
<td>$4.9</td>
<td>$122.00</td>
<td>$79.3K</td>
<td>211</td>
<td align="right">197</td>
</tr>
</tbody>
</table>
</p>
<h3>About Snowflake</h3>
<p>Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.</p>
<p>Having examined the options trading patterns of Snowflake, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Snowflake Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,071,577, with SNOW's price up by 0.63%, positioned at $126.75.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 2 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Snowflake options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


SNOW

Looking At Snowflake's Recent Unusual Options Activity

Offerings

MDAI

Spectral AI Files For Common Stock Offering Of Up To 1.6M Shares

Analyst Ratings

ACRS

Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrades Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials

<p><strong>MicroStrategy Incorporated</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares are trading higher Monday after the company acquired 51,780 additional <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>). Here&#8217;s <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42042019/bitcoin-buyer-spree-microstrategy-acquires-4-6b-in-btc-metaplanet-issues-11-4m-in-bonds-to-fund-purchases">what you need to know.</a></p>
<p><strong>What To Know: </strong>MicroStrategy announced in a new SEC filing that it purchased approximately 51,780 Bitcoins for approximately $4.6 billion in cash between Nov. 11 and Nov. 17. The purchases, made at an average price of $88,627, were funded through proceeds from the issuance and sale of shares under the company&#8217;s Sales Agreement entered into on Oct. 30.</p>
<p>MicroStrategy and its subsidiaries now hold 331,200 Bitcoins, acquired for a total purchase price of about $16.5 billion, or $49,874 per Bitcoin. Based on Monday&#8217;s bitcoin prices, MicroStrategy now has more than $24 billion in Bitcoin holdings and $11.7 billion in unrealized profits.</p>
<p>MicroStrategy said it sold an aggregate of 13,593,865 shares under the Sales Agreement between Nov. 11 and Nov. 17. The company had approximately $15.3 billion worth of shares remaining for issuance and sales under the Sales Agreement as of Nov. 17.</p>
<p>MicroStrategy continues to view Bitcoin as a strategic reserve asset, providing exposure to digital assets as an alternative to traditional money. <strong>Michael Saylor</strong>, the company's co-founder and executive chairman, has emphasized the value of Bitcoin in improving balance sheets and stockholder returns.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/24/11/42028334/bitcoin-ethereum-dogecoin-slip-as-feds-hawkish-stance-tempers-rally-analyst-expects-btc-to-reach-100k-before-new-year">Bitcoin, Ethereum, Dogecoin Slip As Fed&#8217;s Hawkish Stance Tempers Rally: Analyst Expects BTC To Reach $100K Before New Year</a></strong></p>
<p>Bitcoin was up about 0.5% over a 24-hour period, trading around $90,600 at the time of writing, per <a href="http://pro.benzinga.com">Benzinga Pro</a>. It&#8217;s up more than 6% over the past week, driven by several factors, the most important of which appears to be <strong>Donald Trump&#8217;s</strong> election victory. </p>
<p>Trump has positioned himself as pro-crypto and many expect softer crypto regulations amid Trump&#8217;s return to the White House. Bitcoin and broader crypto markets also surged last week as Bitcoin ETFS saw record net inflows of $1.114 billion. Many expect Bitcoin to <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42046847/bitcoin-could-hit-200000-within-260-days-if-this-technical-indicator-is-correct">cross above the $100,000 level</a> by the end of the year. </p>
<p><strong>Price Action:</strong> MicroStrategy shares were up 8.96% at $371.37 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/technicals/24/11/42045952/walmart-q3-earnings-preview-will-bulls-keep-riding-high">Walmart Q3 Earnings Preview: Will Bulls Keep Riding High?</a></strong></li>
</ul>
<p><em>Image via Shutterstock.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$BTC

MSTR

MicroStrategy Shares Are Surging Monday: What's Going On?

<p><strong>GameStop Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) could be pushing deeper into its bets on trading cards and grading services with <a href="https://www.benzinga.com/general/gaming/24/05/38799011/gamestop-dives-into-collectibles-market-with-pok-mon-trading-cards">a new board appointment</a>.</p>
<p><strong>What Happened</strong>: <strong>Nat Turner</strong> officially joined the video game retailer&#8217;s board of directors. The decision expands the number of board members from five to six. </p>
<p>Turner is well-known in the trading card community and is the <a href="https://www.benzinga.com/news/24/10/41337770/whats-going-on-with-gamestop-stock-today">CEO and chairman of <strong>Collectors</strong>.</a></p>
<p>Turner, whose role as director will expire at the company's 2025 annual stockholder meeting, will receive no compensation for his role as a director.</p>
<p>The appointment comes about a month after GameStop entered into a collaboration with<strong> Collectors Holdings</strong> as an authorized PSA dealer.</p>
<p>Turner <a href="https://www.globenewswire.com/news-release/2020/11/30/2136654/0/en/Collectors-Universe-to-be-Acquired-by-Investor-Group-Led-by-Entrepreneur-and-Collector-Nat-Turner-for-Approximately-700-Million.html">bought </a>out the former publicly-traded Collectors Universe for $700 million in 2020 with a group that included<strong> Cohen Private Ventures</strong>. He serves as CEO and <a href="https://news.gamestop.com/static-files/3a14a8c9-45ea-4adf-a6be-9d7d283ff940">owns</a> up to a 10% equity interest in its Profession Sports Authenticator. </p>
<p>GameStop said the collaboration with PSA has resulted in around $1.53 million in dollar value of transactions since the beginning of the agreement.</p>
<p><strong>Point72 Asset Management</strong>, the investment company that also owns the Point72 hedge fund ran by <strong>Steve Cohen</strong>, owns Cohen Private Ventures.</p>
<p>Point72 <a href="https://www.benzinga.com/general/gaming/23/01/30412695/gamestop-short-squeeze-anniversary-a-look-back-at-david-vs-goliath-battle-and-whats-next">provided financing to</a> <strong>Melvin Capital</strong>, a company that shorted GameStop, during the short squeeze. While the hedge fund didn't directly short GameStop, the Cohen-led firm helped provide a lifeline to one of the biggest bettors against the video game retailer.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40946963/bitcoin-worth-63-000-pulled-in-33-pack-of-trading-cards-at-gamestop-mind-boggling-story-go">Bitcoin Worth $63,000 Pulled In $33 Pack Of Trading Cards At GameStop: &#8216;Mind-Boggling&#8217; Story Goes Viral, Highlights Crypto Redemption Card</a></strong></p>
<p><strong>Why It's Important:</strong> GameStop is expanding its reach beyond video games.</p>
<p>Adding Turner to the board could signal a continued expansion into collectibles and grading services. Turner has one of the most valuable sports card collections in the world.</p>
<p>Collectors owns several grading services including PSA (trading cards), PCGS (coins) and Wata (video games). The ownership of a video game grading service could be something to watch in the future with Turner on the board.</p>
<p>GameStop's collectibles revenue of $139.4 million in<a href="https://www.benzinga.com/news/earnings/24/09/40803991/gamestop-q2-earnings-highlights-revenue-miss-eps-beat-cash-update-and-more"> the second quarter</a> was down 17.9% year-over-year. The segment saw the lowest year-over-year decline in the quarter, outpacing sharp losses from the hardware (-24.4%) and software (-47.7%) segments.</p>
<p>For GameStop investors who can remember the short squeeze of 2021, it's worth pointing out that the new board member is connected to a <a href="https://www.benzinga.com/general/entertainment/23/06/32975000/gamestop-film-dumb-money-stars-paul-dano-pete-davidson-seth-rogen-cast-details-first-traile">figure once viewed</a> as an enemy of the company.</p>
<p><strong>Price Action: </strong>GameStop stock is up 1% to $26.71 on Monday versus a 52-week trading range of $9.95 to $64.83. GameStop stock is up over 60% year-to-date in 2024.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/10/41614177/roaring-kitty-puts-chewy-stock-in-the-litter-box-gamestop-shares-move-higher-after-hours">Roaring Kitty Puts Chewy Stock In The Litter Box, GameStop Shares Move Higher After Hours</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Gaming

Management

GameStop Adds Nat Turner To Board: Does The Move Show Bigger Bet On Trading Cards, Grading?

<p>Analysts' ratings for Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) over the last quarter vary from bullish to bearish, as provided by 19 analysts.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">10</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Boston Scientific and provided 12-month price targets. The average target is $96.63, accompanied by a high estimate of $110.00 and a low estimate of $86.00. This current average reflects an increase of 8.57% from the previous average price target of $89.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960086_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of Boston Scientific's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$98.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Bob Hopkins</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$93.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$94.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$78.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Boston Scientific compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Boston Scientific's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Boston Scientific's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BSX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Boston Scientific analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Boston Scientific</h2>
<p>Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.</p>
<h3>Unraveling the Financial Story of Boston Scientific</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Boston Scientific's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>19.34%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Boston Scientific's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>11.14%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Boston Scientific's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.28%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Boston Scientific's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.25%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Boston Scientific's debt-to-equity ratio is below the industry average at <strong>0.54</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Key Takeaways From Boston Scientific Analyst Ratings

<p>Analysts' ratings for Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $8.25, a high estimate of $15.00, and a low estimate of $5.00. A decline of 45.0% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960078_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Inovio Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Inovio Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Inovio Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Inovio Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Inovio Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/INO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Inovio Pharmaceuticals analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Inovio Pharmaceuticals</h2>
<p>Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.</p>
<h3>Inovio Pharmaceuticals: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Inovio Pharmaceuticals faced challenges, resulting in a decline of approximately <strong>-55.41%</strong> in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-31993.31%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-33.72%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Inovio Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-24.52%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Inovio Pharmaceuticals's debt-to-equity ratio is below the industry average at <strong>0.13</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Landscape: 4 Takes On Inovio Pharmaceuticals

<p>11 analysts have shared their evaluations of Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $189.45, a high estimate of $212.00, and a low estimate of $160.00. A 6.88% drop is evident in the current average compared to the previous average price target of $203.44. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960060_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Chord Energy by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$212.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$168.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$211.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Phillip Jungwirth</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$160.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Noah Hungness</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$208.00</td>
<td>$201.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Chord Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Chord Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Chord Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Chord Energy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CHRD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Chord Energy analyst ratings.</strong></a></p>
<h2>About Chord Energy</h2>
<p>Chord Energy Corp is an independent exploration and production company. The company acquires, exploits, develops, and explores crude oil, natural gas, and natural gas liquids in the Williston Basin.</p>
<h3>Chord Energy: A Financial Overview</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Chord Energy showcased positive performance, achieving a revenue growth rate of <strong>29.12%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>15.48%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Chord Energy's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.55%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Chord Energy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.72%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Chord Energy's debt-to-equity ratio is below the industry average. With a ratio of <b>0.12</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CHRD

Expert Outlook: Chord Energy Through The Eyes Of 11 Analysts

<p>In the last three months, 13 analysts have published ratings on Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Range Resources, presenting an average target of $34.92, a high estimate of $45.00, and a low estimate of $27.00. Highlighting a 5.62% decrease, the current average has fallen from the previous average price target of $37.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960053_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Range Resources's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$39.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$34.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$31.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Umang Choudhary</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Range Resources. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Range Resources compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Range Resources's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Range Resources's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RRC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Range Resources analyst ratings.</strong></a></p>
<h2>About Range Resources</h2>
<p>Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2023, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.14 billion cubic feet equivalent per day. Natural gas accounted for 69% of production.</p>
<h3>Range Resources: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Range Resources's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-0.6%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Range Resources's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>8.89%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Range Resources's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.31%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.7%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.47</strong>, Range Resources adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring Range Resources Through Analyst Insights

<p>Throughout the last three months, 4 analysts have evaluated Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.5, a high estimate of $16.00, and a low estimate of $14.00. This current average reflects an increase of 14.81% from the previous average price target of $13.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960035_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Gambling.com Gr by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Ryan Sigdahl</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jeffrey Stantial</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Gambling.com Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gambling.com Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Gambling.com Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Gambling.com Gr's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GAMB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Gambling.com Gr analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Gambling.com Gr Better</h2>
<p>Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casino and online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.</p>
<h3>Gambling.com Gr's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Gambling.com Gr showcased positive performance, achieving a revenue growth rate of <strong>17.59%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>22.69%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Gambling.com Gr's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.67%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Gambling.com Gr's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>4.26%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Gambling.com Gr's debt-to-equity ratio is below the industry average. With a ratio of <b>0.18</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GAMB

In-Depth Examination Of 4 Analyst Recommendations For Gambling.com Gr

<p>5 analysts have shared their evaluations of Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $82.8, a high estimate of $94.00, and a low estimate of $64.00. Highlighting a 8.2% decrease, the current average has fallen from the previous average price target of $90.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960028_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Acadia Healthcare Co by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Acadia Healthcare Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Acadia Healthcare Co's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Acadia Healthcare Co analyst ratings.</strong></a></p>
<h2>All You Need to Know About Acadia Healthcare Co</h2>
<p>Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.</p>
<h3>Breaking Down Acadia Healthcare Co's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Acadia Healthcare Co's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>8.7%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Acadia Healthcare Co's net margin excels beyond industry benchmarks, reaching <strong>8.35%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Acadia Healthcare Co's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.28%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Acadia Healthcare Co's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.18%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Acadia Healthcare Co's debt-to-equity ratio is below the industry average. With a ratio of <b>0.66</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ACHC

Decoding 5 Analyst Evaluations For Acadia Healthcare Co

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Vistra</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VST, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 66 uncommon options trades for Vistra.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 39% bullish and 45%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $377,116, and 57 are calls, for a total amount of $3,201,254.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $65.0 to $210.0 for Vistra during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Vistra's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vistra's whale activity within a strike price range from $65.0 to $210.0 in the last 30 days. </p>
<h3>Vistra Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960028_0_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$11.9</td>
<td>$11.4</td>
<td>$11.62</td>
<td>$150.00</td>
<td>$348.4K</td>
<td>4.3K</td>
<td>247</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$41.7</td>
<td>$41.1</td>
<td>$41.5</td>
<td>$120.00</td>
<td>$166.0K</td>
<td>4.3K</td>
<td>100</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$7.5</td>
<td>$7.2</td>
<td>$7.38</td>
<td>$160.00</td>
<td>$147.4K</td>
<td>788</td>
<td>388</td>
</tr>
<tr>
<td>VST</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.4</td>
<td>$5.2</td>
<td>$5.4</td>
<td>$130.00</td>
<td>$108.5K</td>
<td>2.3K</td>
<td>1.9K</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$11.7</td>
<td>$11.6</td>
<td>$11.6</td>
<td>$145.00</td>
<td>$91.6K</td>
<td>1.4K</td>
<td>337</td>
</tr>
</tbody>
</table>
</p>
<h3>About Vistra</h3>
<p>Vistra Energy is one of the largest power producers and retail energy providers in the us Following the 2024 Energy Harbor acquisition, Vistra owns 41 gigawatts of nuclear, coal, natural gas, and solar power generation along with one of the largest utility-scale battery projects in the world. Its retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016. It acquired Dynegy in 2018.</p>
<p>Following our analysis of the options activities associated with Vistra, we pivot to a closer look at the company's own performance.</p>
<h3>Vistra's Current Market Status</h3>
<ul>
<li>With a volume of 4,078,647, the price of VST is up 3.6% at $147.26. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 100 days.</li>
</ul>
<h3>What The Experts Say On Vistra</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $148.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Vistra, which currently sits at a price target of $147.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Vistra, which currently sits at a price target of $150. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Vistra, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Looking At Vistra's Recent Unusual Options Activity

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Hess</strong>.</p>
<p>Looking at options history for Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) we detected 10 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 50% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $113,290 and 7, calls, for a total amount of $232,048.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $85.0 to $160.0 for Hess over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Hess's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Hess's whale trades within a strike price range from $85.0 to $160.0 in the last 30 days. </p>
<h3>Hess Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960023_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HES</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.3</td>
<td>$11.1</td>
<td>$11.26</td>
<td>$140.00</td>
<td>$45.0K</td>
<td align="right">57</td>
<td align="right">107</td>
</tr>
<tr>
<td>HES</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$21.2</td>
<td>$19.9</td>
<td>$21.2</td>
<td>$140.00</td>
<td>$42.0K</td>
<td align="right">108</td>
<td align="right">32</td>
</tr>
<tr>
<td>HES</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.1</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$155.00</td>
<td>$39.6K</td>
<td align="right">598</td>
<td align="right">110</td>
</tr>
<tr>
<td>HES</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.0</td>
<td>$13.5</td>
<td>$14.0</td>
<td>$145.00</td>
<td>$35.0K</td>
<td align="right">14</td>
<td align="right">70</td>
</tr>
<tr>
<td>HES</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$13.3</td>
<td>$12.6</td>
<td>$13.3</td>
<td>$145.00</td>
<td>$33.2K</td>
<td align="right">14</td>
<td align="right">25</td>
</tr>
</tbody>
</table>
</p>
<h3>About Hess</h3>
<p>Hess is an independent oil and gas producer with key assets in the Bakken Shale, Guyana, the Gulf of Mexico, and Southeast Asia. At the end of 2023, the company reported net proved reserves of 1.4 billion barrels of oil equivalent. Net production averaged 391 thousand barrels of oil equivalent per day in 2023, at a ratio of 74% oil and natural gas liquids and 26% natural gas.</p>
<p>Having examined the options trading patterns of Hess, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Hess</h3>
<ul>
<li>With a trading volume of 551,925, the price of HES is up by 1.02%, reaching $147.12.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 72 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Hess, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Hess's Options: A Look at What the Big Money is Thinking

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>DexCom</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for DexCom.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 27% bullish and 45%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $232,705, and 6 are calls, for a total amount of $264,821.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $95.0 for DexCom over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of DexCom stands at 671.0, with a total volume reaching 1,728.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $75.0 to $95.0, throughout the last 30 days.</p>
<h3>DexCom Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960018_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$21.6</td>
<td>$21.1</td>
<td>$21.3</td>
<td>$90.00</td>
<td>$95.8K</td>
<td>30</td>
<td align="right">52</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$1.1</td>
<td>$1.0</td>
<td>$1.07</td>
<td>$88.00</td>
<td>$82.7K</td>
<td>0</td>
<td align="right">853</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$80.00</td>
<td>$46.5K</td>
<td>1.9K</td>
<td align="right">211</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.5</td>
<td>$4.4</td>
<td>$4.4</td>
<td>$78.00</td>
<td>$42.2K</td>
<td>0</td>
<td align="right">107</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$21.3</td>
<td>$20.9</td>
<td>$20.9</td>
<td>$75.00</td>
<td>$41.8K</td>
<td>24</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About DexCom</h3>
<p>Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.</p>
<p>Having examined the options trading patterns of DexCom, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of DexCom</h3>
<ul>
<li>With a trading volume of 2,245,122, the price of DXCM is up by 1.15%, reaching $76.75.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 80 days from now.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $96.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Bernstein has decided to maintain their Outperform rating on DexCom, which currently sits at a price target of $86.<br />
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for DexCom, targeting a price of $115.<br />
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on DexCom, which currently sits at a price target of $105.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on DexCom with a target price of $90.<br />
&#x2A; An analyst from Leerink Partners has decided to maintain their Outperform rating on DexCom, which currently sits at a price target of $87. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


DXCM

DexCom's Options Frenzy: What You Need to Know

<p><a href="https://abbott.mediaroom.com/press-releases?item=124678" title="https://abbott.mediaroom.com/press-releases?item=124678">https://abbott.mediaroom.com/press-releases?item=124678</a></p>


Biotech

General

Abbott's Amplatzer Amulet Device Demonstrates Superior Long-Term Stroke Prevention And Reduced Blood-Thinner Use In AFib Patients Compared To Watchman; Five-Year Data Presented At AHA 2024 And Published In JACC

<p><i>New zerlasiran data show significant time-averaged Lp(a) reductions with effects persisting 60 weeks following the first dose</i></p>
<p><i>Represents first study to report time-averaged Lp(a) results to further evaluate potential clinical benefits</i></p>
<p><i>Data simultaneously published in the Journal of the American Medical Association</i></p>
<p>Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2024 in Chicago, Illinois, and simultaneously published in the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjama%2Ffullarticle%2F10.1001%2Fjama.2024.21957%3Futm_source%3Djamanetwork.com%26utm_medium%3Dqrcode%26utm_campaign%3Dauthor-2024%26utm_content%3Daha%26utm_term%3D20241118&amp;esheet=54154524&amp;newsitemid=20241118316596&amp;lan=en-US&amp;anchor=Journal+of+the+American+Medical+Association+%28JAMA%29&amp;index=1&amp;md5=49a9a988a542c0ab290345c5dbad6ac5">Journal of the American Medical Association (JAMA)</a>.</p>
<p>Results presented today showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over 36 weeks. This is the first study to report time-averaged Lp(a) analyses, which more accurately evaluates the effects of treatment over time, including intervals between doses. Maximum Lp(a) reductions exceeded 90%. At the final visit, 60 weeks following initial drug administration, reductions in Lp(a) persisted and no safety concerns emerged with infrequent dosing.</p>


Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data At 2024 AHA Annual Meeting; New Zerlasiran Data Show Significant Time-Averaged Lp(a) Reductions With Effects Persisting 60 Weeks Following The First Dose

Rumors

PNNT

Watching Shares Of Pennant Investment; Traders Circulating Co Named As Zack's Pick

Eli Lilly Says Muvalaplin Met Secondary Endpoints For All Three Tested Doses

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX – Research Report), Taked...

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Takeda Pharmaceutical Company (TAK) and Voyager Therapeutics (VYGR)

Scotiabank raised the firm's price target on Travere Therapeutics (TVTX) to $27 from $23 and keeps an Outperform rating on the shares. The company ...

Travere Therapeutics price target raised to $27 from $23 at Scotiabank

In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Travere Therapeutics (TVTX – Research Report)...

Travere Therapeutics (TVTX) Gets a Buy from Bank of America Securities

Stifel Nicolaus analyst Alex Thompson CFA maintained a Hold rating on Travere Therapeutics (TVTX – Research Report) yesterday and set a price targe...

Stifel Nicolaus Remains a Hold on Travere Therapeutics (TVTX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Madrigal Pharmaceuticals (MDGL – Research Report), Travere Therap...

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Travere Therapeutics (TVTX) and Regeneron (REGN)

Travere Therapeutics (TVTX) announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditi...

Travere Therapeutics announces common stock offering, no amount given

Travere Therapeutics announces proposed offering of common stock

The deal priced below last closing price of $17.66. Jefferies and Leerink are acting as joint book running managers for the offering. Published fir...

Travere Therapeutics 7.81M share Spot Secondary priced at $16.00

Travere Therapeutics prices $125M equity offering

The U.K.'s Medicines and Healthcare products Regulatory Agency has approved Travere Therapeutics (TVTX)' medicine sparsentan, or Filspari, to treat...

MHRA approves Travere's sparsentan to treat adults with primary IgAN

MDGL

REGN

VYGR

Health Care

Press Releases

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

Travere Therapeutics to Present at Upcoming Investor Conferences

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

IPOs

Travere Therapeutics Announces Proposed Public Offering of Common Stock

Dividends

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AGEN

LGND

VKTX

VRNA

Akero Therapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Beam Therapeutics

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Galapagos NV - American Depositary Shares

Galapagos

Immunocore Holdings plc - American Depositary Shares

Immunocore Hldgs

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MiMedx Group

MannKind

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Arcus Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Upstream Bio

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Xencor

Piper Sandler

Scotiabank

Barclays

Wells Fargo

Leerink Partners

<p>금요일 오전 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:</p>
<p><strong>1. 코스트코 홀세일</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>)는 4분기 긍정적인 실적을 발표했지만, 매출은 예상에 미치지 못했다. 이 회사는 <a href="https://www.benzinga.com/news/earnings/24/09/41056967/costco-q4-earnings-revenue-miss-eps-beat-comps-climb-5-4-shares-slide">분기 매출이 796.97억 달러</a>로, 컨센서스 추정치인 799.73억 달러를 밑돌았다고 보고했다. 이 회원제 소매업체는 분기당 주당 순이익이 5.29달러로, 애널리스트 추정치인 5.08달러를 초과했다고 보고했다. 코스트코의 주식은 시간외 거래에서 1.4% 하락한 888.62달러에 거래되었다.</p>
<p><strong>2. 무빙 이미지 테크놀로지스</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#NYSE">MITQ</a>)는 4분기 재무 및 운영 실적을 발표할 예정이다. 무빙 이미지 테크놀로지스의 주식은 시간외 거래에서 5% 상승하여 0.5985달러에 거래되었다.</p>
<p><strong>3. 스콜라스틱 코퍼레이션</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>)은 목요일 시장 마감 후 1분기 실적이 예상보다 좋다고 발표했다. 스콜라스틱은 주당 손실이 2.13달러로 예상 손실 2.48달러보다 좋았다고 보고했다. 이 회사는 분기 매출이 2억 3,720만 달러로 애널리스트 컨센서스 추정치인 2억 3,348만 달러를 초과했다고 보고했다. 스콜라스틱의 주식은 시간외 거래에서 6.5% 상승하여 32.13달러에 거래되었다.</p>
<p><em>프리마켓 보도를 확인하려면 <a href="https://www.benzinga.com/premarket/">여기를 클릭하세요</a>.</em></p>
<p><strong>4. 이엔비베노 메디컬 코퍼레이션</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) 공모를 제안했습니다. 이 회사의 주식은 시간외 거래에서 15.6% 하락하여 3.80달러에 거래되었다.</p>
<p><strong>5. 트래비어 테라퓨틱스</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>)는 페그티바티나제(Pegtibatinase)에 대한 3상 하모니(HARMONY) 연구 등록을 자발적으로 중단한다고 발표했다. 트래비어 테라퓨틱스의 주가는 시간외 거래에서 5.3% 하락한 14.24달러를 기록했다.</p>
<p><em><strong>이것도 확인하세요:</strong></em></p>
<ul>
<li><em><strong><a href="https://www.benzinga.com/markets/24/09/41054730/top-3-tech-stocks-that-are-ticking-portfolio-bombs">포트폴리오 폭탄이 될 수 있는 상위 3개 기술 주식</a></strong></em></li>
</ul>
<p><em>사진 출처: Flickr</em></p>
<p><strong>Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요</strong><br />
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요.<br />
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener"><strong>여기를 클릭</strong></a>하여 14일 무료 체험을 시작하세요.</p>

Comments

Travere Therapeutics

뉴스

에 대한 최신 뉴스 Travere Therapeutics (NASDAQ:TVTX) 주식

금요일, 9월 27, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌